Impact Biomedical (IBO) Common Equity (2022 - 2026)

Impact Biomedical (IBO) has reported Common Equity for 5 consecutive years, with $14.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 289.86% year-over-year to $14.0 million; the trailing twelve-month figure through Jun 2026 stood at $14.0 million (up 289.86% YoY), and the FY2025 full-year result was $15.6 million, down 99.61% from the prior year.
• Common Equity declined to $14.0 million in Q2 2026 per IBO's latest filing, from $14.7 million in the prior quarter.
• Across five years, Common Equity topped out at $38.4 million in Q2 2022 and bottomed at -$11.8 million in Q3 2025.
• Historically, Common Equity has averaged $20.9 million across 5 years, with a median of $27.3 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Common Equity sank 134.38% in 2025, then jumped 289.86% in 2026.
• Over 5 years, Common Equity stood at $32.7 million in 2022, then fell by 13.49% to $28.3 million in 2023, then sank by 74.39% to $7.2 million in 2024, then surged by 114.94% to $15.6 million in 2025, then fell by 9.92% to $14.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $14.0 million, $14.7 million, and $15.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.